HIGHLIGHTS
- who: Lan Shu et al. from the Department of General Surgery, Comprehensive Health Center, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China have published the article: Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer, in the Journal: Cancers 2022, 4250 of /2022/
- what: The authors aimed to evaluate whether mRNA levels tested by reverse transcriptase-polymerase chain reaction (qRT-PCR) could better define tumors. The authors focused on the HER2-negative population and first . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.